News Archives

Faron Announces R&D Day

10.9.2026

Faron Pharmaceuticals Ltd | Press Release | September 10, 2026 at 09:00:00 EEST

Faron announces R&D Day to be held on 8 October 2026

The event will provide an opportunity for Faron’s senior management team, together with leading external clinical experts, to review progress across the company’s bexmarilimab clinical development program and to discuss the scientific rationale and clinical opportunity across both hematological and solid tumor indications.

The agenda is as follows:

Welcome and opening remarks — Tuomo Pätsi, MSc, Chairman
Key priorities and vision — Juho Jalkanen, MD, PhD, CEO
Blood Cancer United & TAP: tackling unmet needs in HR-MDS — Blaine Robinson, PhD — VP, Therapy Acceleration Program (TAP), Blood Cancer United
BEXERA and the evolving MDS treatment landscape — Amer Zeidan, MD, MBBS, MHS — Chief, Division of Hematologic Malignancies at Yale Cancer Center and Professor of Medicine at Yale School of Medicine
MDS: inside the bexmarilimab data — Maija Hollmén, PhD, CSO
Pipeline review — Petri Bono, MD, PhD, CMO
BEXAR: expanding bexmarilimab into sarcomas — César Serrano, MD, PhD — Group Leader of the Sarcoma Translational Research Program at the Vall d’Hebron Institute of Oncology
Bexmarilimab market opportunity — Ralph Hughes, MSc, BSc, CBO
Panel Q&A
Closing remarks and outlook — Juho Jalkanen, MD, PhD, CEO

Dr. Juho Jalkanen, Chief Executive Officer of Faron, commented: “I am delighted to be hosting this R&D Day to provide a deep dive into our science and clinical program alongside our management team and leading experts in the field. This is an important opportunity to share our progress and vision with investors and the wider oncology community.”

The event will be held as a webcast. It will begin at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on Thursday, 8 October. The event will last approximately 3 hours.

Webcast registration link: FARON R&D DAY 2026

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers and solid tumors in combination with other standard treatments. Further information is available at www.faron.com.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

7.9.2026

Faron Pharmaceuticals Ltd | Company announcement | September 07, 2026 at 18:30:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			04/09/2026
6. Date on which issuer notified (DD/MM/YYYY):			04/09/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	8.95%	11.30%		20.25%	46,154,796
Position of previous notification (if applicable)	9.41%	11.30%		20.72%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
		20,394,796		25,760,000			8.95%		11.30%


SUBTOTAL 8. A		46,154,796					20.25%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			10,080,000			4.42%
Convertible Bond		12/02/2028	Anytime until maturity			15,680,000			6.88%

			SUBTOTAL 8. B 1			25,760,000			11.30%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	8.95%	11.30%	20.25%
CVI Investments, Inc.	8.95%	11.30%	20.25%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	04.09.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

4.9.2026

Faron Pharmaceuticals Ltd | Company announcement | September 04, 2026 at 13:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer					X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of shares
An acquisition or disposal of financial instruments					X
An event changing the breakdown of shares outstanding
Other (please specify):
3. Details of person subject to the notification obligation
Name			Pentwater Capital Management LP
City and country of registered office (if applicable)			Naples, United States
4. Full name of shareholder(s) (if different from 3.)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached:			01/09/2026
6. Date on which issuer notified (DD/MM/YYYY):			02/09/2026
7. Total positions of person(s) subject to the notification obligation
	% of shares outstanding (total of 8. A)	% of shares outstanding through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)		Total number of shares outstanding held in issuer
Resulting situation on the date on which threshold was crossed or reached		Less than 3%		Less than 3%
Position of previous notification (if applicable)		3.875746%		3.875746%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^v
A: Shares
Class/type of shares ISIN code (if possible)	Number of shares outstanding		% of shares outstanding
	Direct	Indirect	Direct	Indirect

SUBTOTAL 8. A

B 1: Financial Instruments as an entitlement to acquire
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Number shares that may be acquired if the instrument is exercised/converted.	% of shares outstanding

		SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Physical or cash settlement	Number of shares	% of shares outstanding
Swap			Cash Settlement	Less than 3%	Less than 3%

			SUBTOTAL 8.B.2	Less than 3%	Less than 3%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the shares and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)				X
Name	% of shares outstanding if it equals or is higher than the notifiable threshold	% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Matthew Halbower
MCH PWCM Holdings Inc.
Pentwater Capital Management LP		Less than 3%	Less than 3%

10. Additional information

Place of completion	Naples
Date of completion	02/09/2026

Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial

27.8.2026

Faron Pharmaceuticals Ltd | Press Release | August 27, 2026 at 09:00:00 EEST

First clinical evaluation of bexmarilimab plus chemotherapy in a solid tumor with limited treatment options

The BEXAR trial evaluates Faron’s lead asset, bexmarilimab, in combination with standard-of-care doxorubicin as a first-line treatment for patients with metastatic soft-tissue sarcoma.

The trial is sponsored by the international oncology research company MEDSIR and currently conducted at six hospitals across Spain, led by the Vall d’Hebron University Hospital in Barcelona. The Phase 1b/2 BEXAR trial is designed to evaluate the safety and tolerability of bexmarilimab in combination with doxorubicin in the Phase 1b stage, followed by a contingent randomized Phase 2 assessment of preliminary efficacy versus doxorubicin alone.

Dr. César Serrano, Group Leader of the Sarcoma Translational Research Program at the Vall d’Hebron Institute of Oncology and a member of the Sarcoma Faculty of the European Society of Medical Oncology, and scientific and clinical lead of the trial said, “Metastatic soft-tissue sarcoma has seen limited therapeutic progress in decades, and remains particularly difficult to treat. By combining doxorubicin with bexmarilimab, we aim to test whether reprogramming immunosuppressive macrophages can help ignite an anti-tumor response and translate into clinical benefit.”

This enrollment marks the first patient treated with bexmarilimab in the BEXAR trial and the first clinical evaluation of an anti-Clever-1 strategy in combination with doxorubicin in patients with soft-tissue sarcoma. Soft-tissue sarcomas are highly aggressive malignancies and many subtypes are characterized by an immunologically inactive tumor microenvironment heavily dominated by immunosuppressive macrophages. These tumors express some of the highest levels of Clever-1, the target receptor of bexmarilimab, providing a strong mechanistic rationale for this combination strategy.

Dr. Petri Bono, Chief Medical Officer at Faron, commented, “The initiation of patient enrollment in the BEXAR trial is a significant milestone for our solid tumor strategy. Sarcomas express exceptionally high levels of Clever-1, providing a strong biological rationale for investigating an anti-Clever-1 approach in this setting. By combining bexmarilimab with chemotherapy, this trial is the first opportunity to generate clinical evidence for bexmarilimab’s mechanism in soft-tissue sarcomas. If this combination shows evidence of synergy, it could support the rationale for exploring bexmarilimab with other chemotherapy backbones across Clever-1-expressing tumor types. We are proud to support the world-class team at Vall d’Hebron and look forward to the data this trial will generate.”

About bexmarilimab

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers or solid tumors in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

Faron Pharmaceuticals Ltd: Half-year financial results 1 January – 30 June 2026

26.8.2026

Faron Pharmaceuticals Ltd | Company announcement | August 26, 2026 at 09:00:00 EEST

Strengthened balance sheet supports advancement into randomized Phase 2b trial in higher-risk MDS

TURKU, Finland – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, has published its unaudited half-year financial results for the six months ended 30 June 2026, on 26 August 2026.

Figures in parentheses refer to the corresponding period of previous year, unless otherwise indicated.

This half-year report is unaudited. The unaudited interim financial report incorporates the Company, Faron Pharmaceuticals Ltd only. Following the liquidation and closure of the Company’s subsidiaries during the reporting period, the Company no longer has subsidiaries and therefore does not prepare consolidated financial information. The comparative figures have been adjusted to include only the Company’s figures.

January – June 2026 in brief

27 January 2026 – Faron announced a significant expansion to the scope of clinical trials involving bexmarilimab by supporting the investigator-initiated trial (IIT) BEXAR, building evidence on the role of the Clever-1 pathway in solid tumors. The BEXAR trial evaluates Faron’s lead asset, bexmarilimab, in combination with standard-of-care (SoC) doxorubicin for patients with metastatic soft-tissue sarcoma.
9 February 2026 – Faron announced that it is planning a rights issue of approximately EUR 40 million to strengthen its capital structure and to drive its lead asset bexmarilimab to key value-creating milestones and convened an Extraordinary General Meeting to approve the related authorization to the Board of Directors.
19 February 2026 – Faron announced the Phase 2 BEAM IIT, led by the Nordic AML Group, evaluating bexmarilimab in combination with azacitidine to prevent relapse in measurable residual disease (MRD)-positive acute myeloid leukemia (AML) after allogeneic stem cell transplantation.
2 March 2026 – Faron and City of Hope (US) announced the development of a Phase 2 IIT of bexmarilimab in combination with an oral hypomethylating agent (HMA) in relapsed/refractory (r/r) myelodysplastic syndrome (MDS).
26 March 2026 – Faron appointed Mr. Heikki Jouttijärvi as Chief Technical Officer (CTO) to strengthen late-stage development, manufacturing and supply chain activities.
9 April 2026 – Faron published the final results of its rights issue, raising gross proceeds of approximately EUR 40.1 million.
16 April 2026 – Faron announced a collaboration with Parexel, a global clinical research organization, to support the randomized Phase 2b BEXERA trial (FP2CLI012) in frontline, treatment-naïve higher-risk (HR) MDS, planned to start in the second half of 2026.
4 May 2026 – The Annual General Meeting (AGM) adopted the 2025 financial statements, re-elected the auditor, approved a new stock option plan and elected Dr. George Stanley Golumbeski as a new member of the Board of Directors.
15 June 2026 – Faron announced the matured BEXMAB data presented at the European Hematology Association (EHA) 2026 Congress confirming durable efficacy and bone marrow reprogramming in HR-MDS. Median duration of complete remission (CR) in treatment-naïve HR-MDS patients extended to 16.1 months with bexmarilimab + azacitidine.
R&D expenses were EUR 7.6 (7.1) million.
Operating loss for the reporting period was EUR -11.1 (-11.8) million.
Loss per share was EUR 0.06 (0.18).
On 30 June 2026, cash and cash equivalents were EUR 32.0 (13.5) million.
Net assets were EUR 11.6 (-16.7) million.

Significant events after the reporting period

1 July 2026 – The Company’ Board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company under the Company’s Share Option Plan 2026.
13 July 2026 – Faron provided an update on its portfolio of Investigator-Initiated Trials (IITs) evaluating bexmarilimab, its wholly owned anti-Clever-1 immunotherapy, in multiple oncology indications. The update covers five IITs in solid tumors and hematological malignancies, reflecting both advances and adjustments across the program.
27 July 2026 – Faron announced that it has conducted its first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients enrolled in the BEXMAB trial. At this time, after a median follow-up of 14.9 months, the only subgroup to have hit the median is the biallelic TP53 mutated population. This subgroup, historically associated with very poor outcomes, achieved a median OS of 8.8 months, which is in line with historical data and reassuring given the complex cytogenetics within the BEXMAB biallelic patient population.
3 August 2026 – Faron approved the exercise of 3,657,321 special rights entitling to 3,657,321 shares in the Company, for an aggregate subscription price of EUR 1,578,499.74 in connection with the scheduled amortisation payment of the First and Second Tranche Bonds.

Key figures, IFRS

EUR ’000 unless otherwise indicated	1-6/2026 (Unaudited)	1-6/2025 (Unaudited)	1-12/2025 (Audited)
Other operating income	–	–	1,308
Research and development expenses	(7,592)	(7,095)	(12,628)
General and administrative expenses	(3,510)	(4,736)	(7,570)
Operative loss for the reporting period	(11,103)	(11,831)	(18,890)
Loss per share EUR	(0.06)	(0.18)	(0.24)
Number of shares at end of period	202,881,315	111,954,597	114,420,465
Average number of shares	152,771,955	107,403,444	111,718,219
Cash and cash equivalents	31,977	13,509	12,308
Equity	11,558	(16,714)	(18,984)
Balance sheet total	35,811	16,828	17,826

Outlook for 2026

Due to the nature of Faron Pharmaceuticals’ business, the Company does not provide a short-term outlook.

CEO Statement

“The first half of 2026 was a demanding period for Faron, which we successfully navigated with determination and hard work. We began the year with two main themes: advancing bexmarilimab’s development in HR-MDS and demonstrating that our lead asset is also suitable in other indications, especially in solid tumors. I am proud to say that we made decisive progress on both of these fronts during the first half and are very enthusiastic about the future.

Successful rights issue supports Faron’s lead position in HR-MDS

In April, we completed one of Finland’s largest biotechnology financing rounds ever with our EUR 40.1 million rights issue. We are very pleased with the results of the rights issue, which reflect the strong commitment and trust of both our existing shareholders and new cornerstone investors. The raised funds provide a decisive foundation for our next chapter and our most important value driver: the upcoming randomized Phase 2b BEXERA trial in frontline HR-MDS.

Preparations for the BEXERA trial are well underway, and we expect the trial to begin as planned in the second half of 2026. The trial is expected to enrol 90 participants across up to 35 sites in the United States (US), Europe and the United Kingdom (UK). The objective of the trial is to select the recommended Phase 3 dose and demonstrate the efficacy and safety of combining bexmarilimab with SoC azacitidine in a frontline randomized, placebo-controlled setting to support future registrational filings. In April, we entered into an agreement with Parexel, a leading global clinical research organization, to support the trial. The collaboration is focused on ensuring disciplined trial execution, timely delivery and operational efficiency as the program progresses.

Bexmarilimab continues to stand out as one of the most innovative and advanced development programmes in HR-MDS. In June, we presented matured data from the BEXMAB Phase 1/2 study at the EHA 2026 Congress, further reinforcing the clinical and biological potential of bexmarilimab to induce haematopoiesis, activate T cells and overcome treatment resistance in the bone marrow microenvironment. In our view, bexmarilimab remains at the forefront of innovation in MDS, representing a novel mechanism with the potential to transform treatment outcomes. While the field is attracting increasing interest from both existing players and new entrants, most competing approaches are built on previously failed treatment methods, such as BCL-2 and CD47 inhibitors. We have adapted our trial design based on clinical learnings, including redefining the approval endpoint to CR, and are now seeing others in the field beginning to follow a similar path. With our strengthened balance sheet, we are well positioned to advance the program, generate further clinical evidence and maintain strategic flexibility while continuing partnering discussions.

Investigator-initiated trials provide evidence in solid tumors

While our primary focus remains in HR-MDS, we continue to demonstrate bexmarilimab’s potential in solid tumors through a growing number of IITs. Last year, two articles were published in the Journal for ImmunoTherapy of Cancer, highlighting the significance of Clever-1 in solid tumors and deepening our understanding of bexmarilimab’s mode of action in the tumor microenvironment. These results contribute to the design of future trials.

IITs require minimal financial investment from Faron and are designed to evaluate bexmarilimab’s potential in overcoming treatment resistance in diseases such as lung cancer, melanoma and sarcoma. In January, we announced support for the BLAZE and BEXAR IITs, which significantly expands the range of clinical settings in which bexmarilimab is being investigated. The BEXAR trial evaluates bexmarilimab in combination with SoC doxorubicin for patients with metastatic soft-tissue sarcoma, while the BLAZE trial aims to overcome resistance to anti-PD-1 therapy in checkpoint-refractory melanoma and non-small cell lung cancer.

In addition to solid tumors, we are expanding our efforts in malignant haematology. While the BEXMAB trial primarily focuses on HR MDS, it also includes patients with AML. Insights gained from these patients have helped shape our AML development strategy and supported plans for a dedicated Phase 2 trial in AML, targeting biologically defined patient population with a differentiated competitive position. In February, we announced the Phase 2 BEAM IIT, led by the Nordic AML Group, evaluating bexmarilimab in combination with azacitidine to prevent relapse in measurable residual disease (MRD)-positive AML after allogeneic stem cell transplantation. This setting is supported by a strong biological rationale and represents a distinct opportunity within the AML treatment landscape. We are excited to advance these trials and generate further clinical evidence of bexmarilimab’s potential to overcome treatment resistance in new indications.

Looking ahead

For the second half of 2026, our priorities are clear: initiate BEXERA, continue generating evidence from our IIT portfolio, and translate this into further value creation for bexmarilimab. With funding in place through the completed EUR 40.1 million rights issue, we can proceed to the next major milestones.

As we move further into later stage development, we have also brought in new world-class expertise. Heikki Jouttijärvi, our new CTO appointed in March, brings decades of experience in biopharma manufacturing, supply chain management and commercial operations. Our new board member, Dr. George Stanley Golumbeski, is a highly experienced biotech business development leader, whose deep understanding of the biotechnology industry will be invaluable as we continue on our journey.

Faron is better positioned than ever to take bexmarilimab to the next major milestones. I want to thank our team, partners, patients and our shareholders for their continued commitment. Your support is instrumental as we work to transform the treatment landscape for patients with aggressive haematological cancers and prove the broader potential of our immunotherapy platform.”

Dr. Juho Jalkanen

Chief Executive Officer

Tables

Income Statement, IFRS

	Unaudited	Unaudited	Audited
EUR ’000	1-6/2026 6 months	1-6/2025 6 months	1-12/2025 12 months
Revenue	–	–	–
Other operating income	–	–	1,308
Research and development expenses	(7,592)	(7,095)	(12,628)
General and administrative expenses	(3,510)	(4,736)	(7,570)
Operating loss	(11,103)	(11,831)	(18,890)
Gain from liquidation of subsidiaries	427	–	–
Financial income	2,994	613	1,536
Financial expense	(828)	(8,126)	(9,832)
Loss before tax	(8,510)	(19,344)	(27,186)
Tax expense	–	–	(6)
Loss for the period	(8,510)	(19,344)	(27,192)

Other comprehensive income / (loss)	–	–	–
Total comprehensive loss for the period	(8,510)	(19,344)	(27,192)

Loss per ordinary share
Basic and diluted loss per share, EUR	(0.06)	(0.18)	(0.24)

Balance Sheet, IFRS

Unaudited

Audited

EUR ‘000	30 June 2026	30 June 2025	31 December 2025
Assets
Non-current assets
Machinery and equipment	–	1	–
Right-of-use-assets	129	249	189
Subsidiary shares	–	18	18
Intangible assets	1,101	1,110	1,117
Prepayments and other receivables	951	562	575
Total non-current assets	2,182	1,940	1,899
Current assets
Prepayments and other receivables	1,652	1,379	3,619
Cash and cash equivalents	31,977	13,509	12,308
Total current assets	33,629	14,888	15,927
Total assets	35,811	16,828	17,826

Equity and liabilities
Capital and reserves attributable to the equity holders of Faron
Share capital	2,691	2,691	2,691
Reserve for invested unrestricted equity	240,103	197,187	201,649
Accumulated deficit	(231,236)	(216,592)	(223,324)
Total equity	11,558	(16,714)	(18,984)
Non-current liabilities
Borrowings	9,228	14,464	14,213
Lease liabilities	11	138	76
Other liabilities	977	3,176	2,526
Total non-current liabilities	10,217	17,778	16,815
Current liabilities
Borrowings	8,543	7,684	10,270
Lease liabilities	134	127	131
Trade payables	2,518	6,733	6,669
Accruals and other current liabilities	2,840	1,220	2,925
Total current liabilities	14,036	15,764	19,995
Total liabilities	24,253	33,542	36,810
Total equity and liabilities	35,811	16,828	17,826

Cash Flow Statement, IFRS

	Unaudited	Unaudited	Audited
	1-6/2026	1-6/2025	1-12/2025
EUR ‘000	6 months	6 months	12 months

Cash flow from operating activities
Loss before tax	(8,510)	(19,344)	(27,186)
Adjustments for:
Depreciation and amortization	168	151	326
R&D loan forgiveness	–	–	(1,308)
Gain from liquidation of subsidiaries	(427)	–	–
Financial items	(2,166)	7,513	8,296
Share-based compensation	598	706	1,822
Adjusted loss from operations before changes in working capital	(10,336)	(10,974)	(18,050)
Change in net working capital
Prepayments and other receivables	1,641	292	(1,961)
Trade payables	(3,086)	736	673
Other liabilities	(837)	(372)	1,443
Cash used in operations	(12,618)	(10,318)	(17,895)
Income tax paid	–	–	(5)
Net cash used in operating activities*	(12,618)	(10,318)	(17,900)

Cash flow from investing activities
Interest received*	116	19	202
Payments for intangible assets	(93)	(101)	(222)
Net cash used in investing activities*	23	(82)	(20)

Cash flow from financing activities
Proceeds from issue of shares	40,079	12,000	12,121
Share issue transaction cost	(7,231)	(676)	(815)
Proceeds from borrowings	–	13,892	25,000
Repayment of borrowings	(468)	(7,993)	(8,890)
Transaction and structuring fees of borrowings	(11)	(2,500)	(6,240)
Interest paid*	(18)	(208)	(391)
Payment of lease liabilities	(72)	(68)	(141)
Net cash from financing activities*	32,279	14,447	20,644
Effect of exchange rate changes on cash and cash equivalents	(15)	–	123
Net increase (+) / decrease (-) in cash and cash equivalents	19,669	4,047	2,847

Cash and cash equivalents at 1 January / 1 July	12,308	9,462	9,462
Cash and cash equivalents at 31 December / 30 June	31,977	13,509	12,308

* Comparative figures revised according to new presentation format implemented year-end 2025

Virtual briefing and Q&A session

A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, and Jurriaan Dekkers, Chief Financial Officer, today at 08:00 am (EDT) / 1:00 pm (BST) / 3:00 pm (EEST) on Wednesday, 26 August 2026.
Webcast registration link: Faron 2026 Half-Year Financial Results

The half-year report and replay of the webcast will be available on the Company’s website at http://www.faron.com/investors.

For more information, please contact:

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi

FINN Partners, US (media)
Alyssa Paldo
+1 847 791-8085
alyssa.paldo@finnpartners.com

Cairn Financial Advisers LLP, Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About BEXMAB

The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical Company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license commercialize its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant London AIM Rule and Helsinki First North requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Faron Half Year Report 2026 Clean Docx

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

19.8.2026

Faron Pharmaceuticals Ltd | Company announcement | August 19, 2026 at 09:00:00 EEST

Faron Pharmaceuticals will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026

TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report its unaudited half-year financial results for the six months ended 30 June 2026, on Wednesday, 26 August 2026.

A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer and Jurriaan Dekkers, Chief Financial Officer at 08:00 am (EDT) / 1:00 pm (BST) / 3:00 pm (EEST) on Wednesday, 26 August 2026. Webcast registration link: Faron 2026 Half-Year Financial Results

The half-year report, presentation, and a replay of the webcast will be published afterward on the Company’s website at: Reports and presentations – Faron

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen		+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo		+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner		+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä		+358 (0)40 555 4727 +358 (0)50 553 8990

About bexmarilimab

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

5.8.2026

Faron Pharmaceuticals Ltd | Company announcement | August 05, 2026 at 14:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			04/08/2026
6. Date on which issuer notified (DD/MM/YYYY):			04/08/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	9.41%	11.30%		20.72%	47,211,351
Position of previous notification (if applicable)	7.99%	12.53%		20.52%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
		21,451,351		25,760,000			9.41%		11.30%


SUBTOTAL 8. A		47,211,351					20.72%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			10,080,000			4.42%
Convertible Bond		12/02/2028	Anytime until maturity			15,680,000			6.88%

			SUBTOTAL 8. B 1			25,760,000			11.30%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	9.41%	11.30%	20.72%
CVI Investments, Inc.	9.41%	11.30%	20.72%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	04.08.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

4.8.2026

Faron Pharmaceuticals Ltd | Company announcement | August 04, 2026 at 16:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						X
Other (please specify) ⁱⁱⁱ: Amortisation of the First and Second Tranche Bonds with treasury shares						X
3. Details of person subject to the notification obligation ^iv
Name			Faron Pharmaceuticals Ltd
City and country of registered office (if applicable)			Turku, Finland
4. Full name of shareholder(s) (if different from 3.) ^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached ^vi:			3.8.2026
6. Date on which issuer notified (DD/MM/YYYY):			3.8.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	9.37%			9.37%	21,342,679
Position of previous notification (if applicable)	10.97%			10.97%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		21,342,679					9.37%


SUBTOTAL 8. A		21,342,679					9.37%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii				x
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd	9.37%		9.37%





10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
3.8.2026 Company announcement: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Place of completion	Turku, Finland
Date of completion	3.8.2026

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

3.8.2026

Faron Pharmaceuticals Ltd | Company announcement | August 03, 2026 at 15:00:00 EEST

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,657,321 special rights entitling to 3,657,321 shares in the Company, for an aggregate subscription price of EUR 1,578,499.74 in connection with the scheduled amortisation payment of the First and Second Tranche Bonds (as defined below), occurred on 3 August 2026.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). On 11 December 2025 the Company announced that it had resolved upon the issuance of a second tranche of convertible bonds amounting to EUR 10 million (the “Second Tranche Bonds”) due 2 December 2028, to HCM, convertible into new and/or existing Shares in the Company. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds and the Second Tranche Bonds.

The Company has received a scheduled amortised payment notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 913,500 for First Tranche bonds and EUR 665,000 for Second Tranche Bonds. Therefore, total aggregate amortised payment amount (including accrued interest) is EUR 1,578,500. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 0.4316 per Share being the lower of i) conversion price on the amortization date (EUR 0.50) or ii) 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date (3 August 2026), and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 3,657,321 Special Rights entitling to 3,657,321 new Shares in total, for an aggregate subscription price of EUR 1,578,500. Of those Shares 2,116,543 are used to amortize the First Tranche Bonds (including accrued interest) and 1,540,778 to amortize the Second Tranche Bonds (including accrued interest). The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and the Second Tranche Bonds and recorded into the reserve for invested unrestricted equity.

The 3,657,321 shares subscribed for are shares already held by the Company in treasury. The Shares rank pari passu in all respects with the existing shares of the Company.

Following the amortisation, the aggregate number of shares in the Company is 227,881,315 and of these shares, the Company holds 21,342,679 in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

27.7.2026

Faron Pharmaceuticals Ltd | Company announcement | July 27, 2026 at 09:00:00 EEST

Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. For patients with biallelic TP53 mutations the median OS is 8.8 months in line with historical results in this highly aggressive population.

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today announced that it has conducted its first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients enrolled in the BEXMAB trial. At this time, after a median follow-up of 14.9 months, the only subgroup to have hit the median is the biallelic TP53 mutated population. This subgroup, historically associated with very poor outcomes, achieved a median OS of 8.8 months, which is in line with historical data and reassuring given the complex cytogenetics within the BEXMAB biallelic patient population. Other subgroups: monoallelic TP53 mutated and wildtype patients have still not reached their median OS.

The BEXMAB trial is an open-label Phase 1/2 study investigating bexmarilimab, Faron’s novel anti-Clever-1 immunotherapy, in combination with standard-of-care azacitidine in patients with higher-risk myelodysplastic syndromes. Of the 21 treatment-naïve HR-MDS patients, 48% harboured TP53 mutations, a well-established adverse prognostic factor associated with inferior survival outcomes. Of the TP53 mutated patients (with known allele frequency data), 33% had monoallelic TP53 alterations, and 67% had biallelic TP53 alterations.

Survival follow-up is ongoing, and several patients remain alive and under follow-up, providing the opportunity for further maturation of the dataset over time.

“These results further support the potential of bexmarilimab in frontline TP53 wild-type and mutated HR-MDS patients, where significant unmet medical need remains,” said Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals. “The data provide additional support as we continue preparations for BEXERA, our planned randomized study evaluating bexmarilimab in combination with azacitidine in frontline HR-MDS patients. We look forward to presenting the detailed full BEXMAB dataset at an upcoming scientific meeting later this year.”

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen		+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo		+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner		+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä		+358 (0)40 555 4727 +358 (0)50 553 8990

About bexmarilimab

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements